We Must Face The Funding Shortfall With New Ideas, Bold Action

Although being an advocate for science has always been rewarding for me, I've recently become somewhat hesitant on the matter--my hesitancy, in part, reflecting the difficulty that a number of my colleagues and I have encountered when speaking about biomedical research policy in Washington.

Written byLeon Rosenberg
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Although being an advocate for science has always been rewarding for me, I've recently become somewhat hesitant on the matter--my hesitancy, in part, reflecting the difficulty that a number of my colleagues and I have encountered when speaking about biomedical research policy in Washington.

If we sound an alarm, we're told that negative messages are poorly received by lawmakers. If we say that current funding constraints are resulting in lost opportunities, we're told that scientists must quit talking about federal support as if it were an entitlement. If we say that people actually engaged in scientific research should have a voice in formulating a collective response to the administration's budget, we're told that scientists are na9ve and self-serving--that we should stay in our labs and let the cognoscenti work their magic on Capitol Hill.

Upon reflection, I've discovered two new pseudoscientific principles that explain this tension:

The first principle is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies